Non-myeloablative stem cell transplantation for autoimmune diseases

被引：0
作者：
Richard K. Burt
Larissa Verda
Yu Oyama
Laisvyde Statkute
Shimon Slavin
机构：
[1] Northwestern University Feinberg School of Medicine,Division of Immunotherapy
[2] Hadassah University,Department of Bone Marrow Transplantation and Cancer Immunotherapy
来源：
Springer Seminars in Immunopathology | 2004年 / 26卷
关键词：
Non-myeloablative stem cell transplantation; Systemic lupus erythematosus; Multiple sclerosis; Scleroderma; Rheumatoid arthritis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Treatment of life-threatening autoimmune diseases in animal models with induced or spontaneous autoimmune diseases can be accomplished by a 2-step procedure involving elimination of self-reactive lymphocytes with an immune ablative conditioning regimen followed by infusion of autologous or allogeneic stem cells, respectively. In animal models it was shown that using such a strategy, autoimmunity could be adequately controlled. It is speculated that de-novo development of the T and B cell repertoire from uncommitted progenitor cells in the presence of the autoantigens may be the best recipe for re-induction of self-tolerance, similarly to the normal ontogeny of the immune system during the induction of self tolerance in fetal stage. For both autologous and allogeneic hematopoietic stem cell transplantation, a non-myeloablative stem cell transplantation (NST) regimen may be used for safer lymphoablation rather than myeloablation. In addition, for allogeneic hematopoietic stem cell transplantation engraftment of disease resistant donor stem cells will alter the genetic predisposition towards autoimmune disease susceptibility.
引用
收藏
页码：57 / 69
页数：12
相关论文
共 156 条
  • [31] Slavin S(1992)Chronic-relapsing experimental autoimmune encephalomyelitis (CR-EAE): treatment and induction of tolerance, with high dose cyclophosphamide followed by syngeneic bone marrow transplantation J Neuroimmunol 39 201-undefined
  • [32] Burns W(2000)High-dose immunosuppressive therapy with PBSC support in the treatment of poor risk multiple sclerosis Bone Marrow Transplant 25 525-undefined
  • [33] Marmont A(1983)Rating neurologic impairment in multiple sclerosis: an extended disability status scale (EDSS) Neurology 33 1444-undefined
  • [34] Burt RK(2001)Autologous hematopoietic stem cell transplantation suppresses gd-enhanced MRI activity in MS Neurology 57 62-undefined
  • [35] Traynor A(1993)Immune ablation with stem-cell rescue: a possible cure for systemic lupus erythematosus? Lupus 2 151-undefined
  • [36] Oyama Y(1997)Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration Lupus 6 545-undefined
  • [37] Burt RK(2002)High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes Blood 100 1602-undefined
  • [38] Traynor A(2003)Non-myeloablative hematopoietic cell transplantation as immunotherapy for hematologic malignancies Cancer Treat Rev 29 283-undefined
  • [39] Ramsey-Goldman R(2002)Irradiation induces neural precursor-cell dysfunction Nat Med 8 955-undefined
  • [40] Burt RK(1979)Transplantation of autoimmune potential. IV. Reversal of the NZB autoimmune syndrome by bone marrow transplantation Transplant 27 133-undefined
12345678910